CAMBRIDGE, Mass., May 16, 2019 /PRNewswire/ -- Blueprint Medicines
Corporation (NASDAQ: BPMC), a precision therapy company focused on
genomically defined cancers, rare diseases and cancer
immunotherapy, today announced the presentation of updated clinical
data for its potent and highly selective investigational medicines
avapritinib and BLU-667.
At the 2019 American Society of Clinical Oncology (ASCO) Annual
Meeting and 24th Congress of the European Hematology
Association (EHA), Blueprint Medicines plans to present:
- Data from the expansion portion of the registration-enabling
ARROW trial of BLU-667 in patients with RET-altered non-small cell
lung cancer (NSCLC) and thyroid cancers
- Data from the registration-enabling NAVIGATOR trial of
avapritinib in patients with PDGFRA Exon 18 mutant and fourth-line
gastrointestinal stromal tumors (GIST), which will be used for
planned marketing applications in the
United States and Europe
- Data from the registration-enabling EXPLORER trial of
avapritinib in patients with advanced systemic mastocytosis
(SM)
"Our upcoming presentations highlight data supporting our plans
for multiple marketing applications in the United States and Europe over the next 18 months and demonstrate
continued progress on our '2020 Blueprint' strategy," said
Andy Boral, M.D., Ph.D., Chief
Medical Officer of Blueprint Medicines. "The datasets reflect the
rapid development of avapritinib and BLU-667, including in four
indications that have received Breakthrough Therapy Designation
from the FDA. These presentations for avapritinib and BLU-667
highlight the breadth and speed of development of our portfolio, as
well as our commitment to rapidly deliver new precision therapies
to cancer patients with limited or no effective treatment
options."
The accepted abstracts are listed below and are now available
online on the ASCO and EHA conference websites, respectively:
https://am.asco.org/ and
https://ehaweb.org/congress/eha24/key-information/.
2019 American Society of Clinical Oncology (ASCO) Annual
Meeting
May 31-June 4,
2019; Chicago,
Illinois
Oral Presentation
Presentation Title: Clinical activity and tolerability of
BLU-667, a highly potent and selective RET inhibitor, in patients
(pts) with advanced RET-fusion+ non-small cell lung cancer
(NSCLC)
Session Title: Lung Cancer—Non-Small Cell Metastatic
Session Date & Time: Monday, June
3, 2019 from 8:00 a.m. –
11:00 a.m. CT (9:00 a.m. – 12:00 p.m.
ET)
Abstract Number: 9008
Poster Discussion Presentations
Presentation Title: Activity and tolerability of BLU-667,
a highly potent and selective RET inhibitor, in patients with
advanced RET-altered thyroid cancers
Session Title: Head and Neck Cancer
Poster Session Date & Time: Saturday, June 1, 2019 from 1:15 p.m. – 4:15 p.m.
CT (2:15 p.m. – 5:15 p.m. ET)
Poster Discussion Session Date & Time: Saturday, June 1, 2019 from 4:30 – 6:00 p.m. CT (5:30
p.m. – 7:00 p.m. ET)
Abstract Number: 6018
Presentation Title: Clinical activity of avapritinib in ≥
fourth line (4L+) and PDGFRA Exon 18 gastrointestinal stromal
tumors (GIST)
Session Title: Sarcoma
Poster Session Date & Time: Saturday, June 1, 2019 from 8:00 a.m. – 11:00 a.m.
CT (9:00 a.m. – 12:00 p.m. ET)
Poster Discussion Session Date & Time: Saturday, June 1, 2019 from 3:00 p.m. – 4:30 p.m.
CT (4:00 p.m. – 5:30 p.m. ET)
Abstract Number: 11022
24th Congress of the European Hematology
Association (EHA)
June 13-16,
2019; Amsterdam, The
Netherlands
Oral Presentation
Presentation Title: Avapritinib, a potent and selective
inhibitor of KIT D816V, induces complete and durable responses in
patients (pts) with advanced systemic mastocytosis (AdvSM)
Session Title: New Agents in MPN
Presentation Date & Time: Saturday, June 15, 2019 from 12:00 p.m. – 12:15 p.m.
CEST (6:00 a.m. – 6:15 a.m. ET)
Abstract Number: S830
Investor Event and Webcast Information
Blueprint Medicines will host an investor event on Monday, June 3, 2019 beginning at 6:30 p.m. CT (7:30 p.m.
ET) in Chicago to provide a
portfolio update, including a review of updated clinical data from
the ongoing ARROW trial of BLU-667 in patients with RET-altered
cancers and the ongoing registration-enabling NAVIGATOR trial in
patients with PDGFRA Exon 18 mutant and fourth-line GIST. The event
will be webcast live and can be accessed under the "Investors &
Media—Events & Presentations" section of Blueprint Medicines'
website at www.BlueprintMedicines.com. A replay of the webcast will
be available approximately two hours after the event and will be
available for 30 days following the event.
About Blueprint Medicines
Blueprint Medicines is a precision therapy company striving
to improve human health. With a focus on genomically defined
cancers, rare diseases and cancer immunotherapy, we are developing
transformational medicines rooted in our leading expertise in
protein kinases, which are proven drivers of disease. Our uniquely
targeted, scalable approach empowers the rapid design and
development of new treatments and increases the likelihood of
clinical success. We are currently advancing four investigational
medicines in clinical development, along with multiple research
programs. For more information,
visit www.BlueprintMedicines.com and follow us
on Twitter (@BlueprintMeds) and LinkedIn.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, including, without limitation, statements
regarding plans and timelines for submitting marketing applications
for avapritinib and BLU-667 in the United
States and Europe,
including expectations related to the data for such submissions;
and Blueprint Medicines' strategy, goals and anticipated
milestones, business plans and focus. The words "may," "will,"
"could," "would," "should," "expect," "plan," "anticipate,"
"intend," "believe," "estimate," "predict," "project," "potential,"
"continue," "target" and similar expressions are intended to
identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Any
forward-looking statements in this press release are based on
management's current expectations and beliefs and are subject to a
number of risks, uncertainties and important factors that may cause
actual events or results to differ materially from those expressed
or implied by any forward-looking statements contained in this
press release, including, without limitation, risks and
uncertainties related to the delay of any current or planned
clinical trials or the development of Blueprint Medicines' drug
candidates, including avapritinib, BLU-667, BLU-554 and BLU-782;
Blueprint Medicines' advancement of multiple early-stage efforts;
Blueprint Medicines' ability to successfully demonstrate the safety
and efficacy of its drug candidates and gain approval of its drug
candidates on a timely basis, if at all; the preclinical and
clinical results for Blueprint Medicines' drug candidates, which
may not support further development of such drug candidates;
actions of regulatory agencies, which may affect the initiation,
timing and progress of clinical trials; Blueprint Medicines'
ability to develop and commercialize companion diagnostic tests for
its current and future drug candidates; and the success of
Blueprint Medicines' current and future collaborations, including
its cancer immunotherapy collaboration with F. Hoffmann-La Roche
Ltd and Hoffmann-La Roche Inc. and its collaboration with CStone
Pharmaceuticals. These and other risks and uncertainties are
described in greater detail in the section entitled "Risk Factors"
in Blueprint Medicines' Quarterly Report on Form 10-Q for the
period ended March 31, 2019, as filed
with the Securities and Exchange Commission (SEC) on May 9, 2019, and any other filings that Blueprint
Medicines has made or may make with the SEC in the future. Any
forward-looking statements contained in this press release
represent Blueprint Medicines' views only as of the date hereof and
should not be relied upon as representing its views as of any
subsequent date. Except as required by law, Blueprint Medicines
explicitly disclaims any obligation to update any forward-looking
statements.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-announces-data-presentations-at-asco-and-eha-meetings-from-registration-enabling-clinical-trials-of-avapritinib-and-blu-667-across-multiple-patient-populations-300851357.html
SOURCE Blueprint Medicines Corporation